10x Genomics (NASDAQ:TXG) Announces Earnings Results

10x Genomics (NASDAQ:TXG) announced its quarterly earnings data on Thursday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.10, Zacks reports. The business had revenue of $151.04 million during the quarter, compared to analysts’ expectations of $146.67 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.41%. The business’s quarterly revenue was down 12.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 EPS.

Here are the key takeaways from 10x Genomics’ conference call:

• Atera demand exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management cited broad interest from academia, medical centers, and biopharma, with potential utilization estimated at roughly 2x Xenium levels.
• 10x raised its 2026 revenue outlook to $610 million-$630 million, representing 2%-5% growth excluding non-recurring settlement revenue. Q4 is expected to benefit substantially from Atera shipments, alongside normal seasonal strength.
• Q2 revenue was $151 million, or $149.4 million excluding settlement revenue, up 3% year over year; consumables revenue increased 7%, led by 16% growth in spatial consumables and double-digit growth in single-cell reaction volumes. However, total instrument revenue declined 47% as customers moderated purchases ahead of Atera and tariff changes.
• Management expects a modest sequential revenue decline in Q3 as customers defer Xenium and Visium purchases while preparing for Atera, with the spatial transition dynamics expected to peak during the quarter. Atera demand is strong, but near-term shipments remain constrained by manufacturing capacity.
• Executives characterized AI-driven biological research as a significant structural tailwind, increasing demand for high-quality single-cell and spatial data. The company also highlighted continued Flex Apex momentum, expanding multi-omics capabilities, and new oncology partnerships supporting future clinical applications.

10x Genomics Trading Up 14.1%

NASDAQ TXG opened at $52.03 on Friday. The stock has a 50-day moving average of $39.28 and a 200 day moving average of $27.62. The stock has a market capitalization of $6.61 billion, a price-to-earnings ratio of -88.18 and a beta of 2.03. 10x Genomics has a twelve month low of $11.16 and a twelve month high of $52.22.

Analyst Ratings Changes

TXG has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. Leerink Partners lifted their price target on 10x Genomics from $23.00 to $40.00 and gave the company a “market perform” rating in a research report on Friday, July 17th. Bank of America boosted their price target on 10x Genomics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Monday, April 20th. Zacks Research cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Canaccord Genuity Group boosted their target price on shares of 10x Genomics from $32.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $34.83.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 15,098 shares of 10x Genomics stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $368,995.12. Following the completion of the sale, the chief financial officer directly owned 379,898 shares in the company, valued at $9,284,707.12. This trade represents a 3.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Shehnaaz Suliman sold 5,723 shares of 10x Genomics stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total value of $186,741.49. Following the completion of the transaction, the director owned 31,722 shares of the company’s stock, valued at approximately $1,035,088.86. This trade represents a 15.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 91,309 shares of company stock worth $2,581,357. 8.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently made changes to their positions in TXG. &PARTNERS acquired a new position in shares of 10x Genomics during the 4th quarter worth about $218,000. State of Wyoming acquired a new stake in shares of 10x Genomics during the 4th quarter worth about $225,000. Orion Porfolio Solutions LLC acquired a new stake in shares of 10x Genomics during the 2nd quarter worth about $158,000. Vident Advisory LLC purchased a new stake in 10x Genomics during the second quarter worth approximately $162,000. Finally, HUB Investment Partners LLC purchased a new stake in 10x Genomics during the second quarter worth approximately $152,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Key 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q2 results exceeded expectations: 10x Genomics reported an adjusted loss of $0.14 per share, better than the $0.23–$0.24 consensus loss, while revenue of $151.0 million topped estimates near $146.7 million. 10x Genomics Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $610 million to $630 million, with the midpoint slightly above Wall Street’s approximately $613.8 million forecast. The guidance increase signals confidence in demand and supports the stock’s positive reaction. 10x Genomics Raises 2026 Revenue Outlook
• Positive Sentiment: Gross margin improved: Expansion in gross margin adds to the earnings beat and suggests improving operating leverage, even though the company remains unprofitable.
• Neutral Sentiment: Atera shipments remained around 40 units: The company maintained this shipment level while raising its outlook, but investors may be watching for further acceleration in instrument placements. 10x Genomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Sales and earnings remain pressured year over year: Revenue declined 12.7% from the prior-year quarter, and the company posted a loss versus prior-year EPS of $0.28. Continued losses and an expected full-year loss remain risks despite the improved outlook.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.